Hiroaki Suga (菅 裕明, born February 21, 1963) is a Japanese biochemist and businessman.
He is best known for his work on artificial ribozymes (flexizymes) and their application in mRNA display (RaPID, random nonstandard peptide integrated discovery).
[1][2] Suga was awarded the 2023 Wolf Prize in Chemistry, jointly with Chuan He and Jeffery W. Kelly, "for pioneering discoveries that illuminate the functions and pathological dysfunctions of RNA and proteins and for creating strategies to harness the capabilities of these biopolymers in new ways to ameliorate human diseases.
[3] Suga completed his Ph.D. in chemistry at Massachusetts Institute of Technology in 1994 with Satoru Masamune [jp],[3] working on catalytic antibodies[4] After graduating from MIT with a Ph.D., Suga was a postdoctoral researcher at the Jack W. Szostak lab of Harvard Medical School before starting his independent career at University at Buffalo.
[2][8] Suga is chair of the editorial board at RSC Chemical Biology[9] and associate editor at Angewandte Chemie.